Influence of granulocyte colony-stimulating factor on cardiac function in patients with acute myocardial infarction

Shi-Zun Guo1, Ning-Fu Wang, Liang Zhou

  • 1Department of Cardiology, First Municipal Hospital of Hangzhou & Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou, Zhejiang, 310006, China. eagle_sd@163.com

Chinese Medical Journal
|September 8, 2010
PubMed

Insights

Subcutaneous granulocyte colony-stimulating factor (G-CSF) injection is safe for patients with ST-segment elevation myocardial infarction (STEMI). While G-CSF did not significantly improve cardiac function compared to controls, it showed potential for myocardial recovery.

Area of Science:

  • Cardiology
  • Regenerative Medicine
  • Stem Cell Biology

Background:

  • Granulocyte colony-stimulating factor (G-CSF) is explored for improving cardiac function post-myocardial infarction.
  • Previous clinical trials on G-CSF for cardiac repair yielded controversial results.
  • This study focuses on the safety and efficacy of subcutaneous G-CSF in STEMI patients with impaired left ventricular function.

Purpose of the Study:

  • To evaluate the safety and efficacy of subcutaneous G-CSF injection.
  • To assess the impact of G-CSF on left ventricular function after ST-segment elevation myocardial infarction (STEMI).
  • To investigate G-CSF's role in stem cell mobilization for myocardial repair.

Main Methods:

  • Thirty-three STEMI patients with leukopenia were randomized post-percutaneous coronary intervention.
  • The G-CSF group received daily subcutaneous injections (10 microg/kg) for 7 days.
  • Outcomes included blood analyses, echocardiography, angiography, and adverse event monitoring at 6-month follow-up.

Main Results:

  • No severe adverse events were reported in either the G-CSF or control group.
  • Both groups showed significant improvements in segmental wall thickening and left ventricular ejection fraction.
  • No significant differences in cardiac function recovery were observed between the G-CSF and control groups, except for a significant difference in left ventricular ejection fraction measured by angiocardiography (P = 0.046).

Conclusions:

  • Subcutaneous G-CSF administration is safe for STEMI patients.
  • G-CSF appears to be a pragmatic strategy for myocardial global function recovery.
  • Further research may elucidate G-CSF's specific benefits in stem cell mobilization for cardiac repair.
Abstract